0.548
0.01 (1.82%)
| Previous Close | 0.538 |
| Open | 0.530 |
| Volume | 296,927 |
| Avg. Volume (3M) | 317,723 |
| Market Cap | 43,784,888 |
| Price / Sales | 2.25 |
| Price / Book | 3.07 |
| 52 Weeks Range | |
| Earnings Date | 25 Nov 2024 |
| Profit Margin | -176.67% |
| Operating Margin (TTM) | -107.05% |
| Diluted EPS (TTM) | -0.450 |
| Total Debt/Equity (MRQ) | 223.55% |
| Current Ratio (MRQ) | 1.61 |
| Operating Cash Flow (TTM) | -30.35 M |
| Levered Free Cash Flow (TTM) | -15.81 M |
| Return on Assets (TTM) | -35.23% |
| Return on Equity (TTM) | -171.94% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | BioLineRx Ltd. | Bullish | Mixed |
Stockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.88 |
|
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 8.54% |
| % Held by Institutions | 3.07% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Alyeska Investment Group, L.P. | 30 Sep 2024 | 866,495 |
| Cvi Holdings, Llc | 30 Jun 2024 | 815,683 |
| Envestnet Asset Management Inc | 30 Sep 2024 | 239,186 |
| Values First Advisors, Inc. | 30 Sep 2024 | 197,516 |
| Atria Investments, Inc | 30 Sep 2024 | 133,974 |
| Pvg Asset Management Corp | 30 Jun 2024 | 123,580 |
| Atria Wealth Solutions, Inc. | 30 Sep 2024 | 94,133 |
| Lpl Financial Llc | 30 Sep 2024 | 92,000 |
| Orin Green Financial, Llc | 30 Sep 2024 | 43,000 |
| Rathbones Group Plc | 30 Sep 2024 | 39,820 |
| Wells Fargo & Company/Mn | 30 Sep 2024 | 35,035 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 21.00 (HC Wainwright & Co., 3,734.22%) | Buy |
| Median | 11.50 (1,999.69%) | |
| Low | 2.00 (Jones Trading, 265.16%) | Buy |
| Average | 11.50 (1,999.69%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 0.540 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Nov 2024 | 21.00 (3,734.22%) | Buy | 0.450 |
| Jones Trading | 04 Sep 2024 | 2.00 (265.16%) | Buy | 0.630 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2024 | Announcement | BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 |
| 05 Nov 2024 | Announcement | BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 |
| 16 Oct 2024 | Announcement | BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide |
| 17 Sep 2024 | Announcement | BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |